Jun 2, 2026Effective9999999995-26-001854
All companies
424B4Jun 21, 2023
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond Azitra, Inc. Files Form S-1 Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Azitra Inc
AZTRPublicArchived
Public / ArchivedUnited States(NYSE)Best valuation $3.72M1 market
Public listing
Listed· NYSE· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: lifecycle-news, sec-harvest, sec-edgar, nasdaq
IPO Calendar · NYSEIPO
AZTRPrice
$0.2300
24h
+33.95%
Valuation
$3.72M
24h volume
$32.96M
Type
IPO
IPO Calendar · updated 1h ago
Azitra Inc IPO public float & lock-up
Public float and locked shares extracted from Azitra Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
12.09M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001701478.
Revenue · -100.00% YoY
$0
Net income
-$10.96M
Gross margin
—
Cash
$2.07M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $7.5K | $686K | $284K | — |
| Operating income | -$10.97M | -$10.99M | -$7.45M | -$9.45M | — |
| Net income | -$10.96M | -$8.97M | -$11.28M | -$10.68M | — |
| R&D expense | $4.84M | $4.72M | $3.64M | $6.1M | — |
| Cash & equivalents | $2.07M | $4.55M | $1.8M | $3.49M | — |
| Total assets | $5.03M | $7.36M | $5.12M | $7.17M | — |
| Total liabilities | $1.22M | $1.66M | $2.2M | $9.73M | — |
| Shareholders' equity | $3.8M | $5.7M | $2.91M | -$36.26M | -$25.77M |
About Azitra Inc
Azitra is a clinical-stage biopharmaceutical company developing precision dermatology therapies based on microbial engineering, proteins, peptides, and skin-biology research.
What the company does
- Uses genetic engineering and microbiome science to design therapies for dermatological diseases.
- Develops product candidates for rare and treatment-limiting skin conditions, including programs built around engineered live biotherapeutics.
- Combines wet-lab biology with computational screening to identify strains, proteins, and peptides with therapeutic potential.
Business profile
Azitra operates in precision dermatology, where clinical evidence, safety, regulatory progress, intellectual property, and disease-specific differentiation are key.
SEC IPO filings
EffectiveEDGAR filings resolved from AZTR / CIK 0001701478.
S-1S-1
May 21, 2026Filed0001493152-26-024849
424B3424B3
Dec 16, 2025Final prospectus0001493152-25-027900
Dec 15, 2025Effective9999999995-25-003745
CORRESPfilename1.htm
Dec 12, 2025SEC correspondence0001493152-25-027375
S-1S-1
Dec 10, 2025Filed0001493152-25-027067
RWRW
Oct 14, 2025Withdrawn0001493152-25-017936
S-1S-1
Aug 29, 2025Filed0001493152-25-012495
424B3424B3
Jul 24, 2025Final prospectus0001493152-25-011367
Jul 23, 2025Effective9999999995-25-002334
CORRESPfilename1.htm
Jul 22, 2025SEC correspondence0001493152-25-011331
UPLOADfilename1.pdf
Jul 22, 2025SEC correspondence0000000000-25-007694
Latest Azitra Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
StockwatchJun 17, 2026IPO context
Azitra issued a June 17, 2026 letter to shareholders describing strategic reorientation initiatives and outlook for 2026 and beyond, including references to financing completed in March where it raised $10.5 million and potential additional warrant exercises. This is not an IPO filing, but it is fresh company-specific capital/strategy context within the 45-day window.
SECMay 21, 2026IPO filing
Azitra filed a public Form S-1 with the SEC on May 21, 2026 (accession no. 0001493152-26-024849). This is the latest confirmed IPO-related registration activity for the company within the last 45 days.
Azitra, Inc. (PRNewswire-hosted PDF)May 13, 2026IPO context
Azitra reported Q1 2026 results and stated it priced a private placement financing of up to approximately $10.5 million, with up to an additional approximately $20.9 million upon exercise of warrants. While not an IPO event, it is recent capital-markets news tied to the company.
Azitra Inc IPO — frequently asked questions
- When did Azitra Inc go public?
- Azitra Inc has already gone public and now trades publicly on NYSE under the ticker AZTR.
- Can I buy Azitra Inc stock?
- Yes — Azitra Inc is publicly traded on NYSE as AZTR. You can follow its live price, valuation and post-IPO performance above.
- What is Azitra Inc's valuation?
- Azitra Inc's most recent valuation tracked here is $3.72M, derived from live market prices.